Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2024

31 May - 4 Jun 2024

McCormick Place, Chicago, United States of America

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157...

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Highlights in melanoma from ASCO 2024

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

Highlights in melanoma from ASCO 2024 ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Encouraging results using mismatched unrelated donors in stem cell...

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients...

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Importance of MRD in newly developed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

Importance of MRD in newly developed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Cancer advocacy and fundraising in Nigeria

Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation

Cancer advocacy and fundraising in Nigeria ( Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Teclistamab continues to demonstrate deep and durable responses in relapsed...

Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA

$Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma ( Dr Alfred Garfall - Penn Medicine Abramson Cancer Center, Philadelphia, USA )$

Trial argues strongly for the development of 1st-line biomarker selected...

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

ASCO 2024: Advances in NSCLC

Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo

ASCO 2024: Advances in NSCLC ( Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo )

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

Clinical behaviour of breast cancer in young BRCA carriers and prognostic...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Chemotherapy before and after surgery may be new standard treatment for some...

Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer ( Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany )

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post...

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )

Maintenance systemic therapy versus local consolidative therapy plus...

Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC ( Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond...

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan...

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible...

Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis ( Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain )

Melanoma outcomes improved by dual immunotherapy before surgery rather than...

Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands

Melanoma outcomes improved by dual immunotherapy before surgery rather than after ( Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands )

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS...

Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center...

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive disease following docetaxel ( Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center, Madison, USA )

Atezolizumab versus placebo in combination with bevacizumab and non-platinum...

Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer ( Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany )

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy...

Prof Jean-Marc Classe - Nantes Université, Nantes, France

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes ( Prof Jean-Marc Classe - Nantes Université, Nantes, France )

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Telehealth delivery of palliative care an effective alternative to in-person...

Dr Joseph Greer - Harvard Medical School, Boston, USA

Telehealth delivery of palliative care an effective alternative to in-person visits for patients with advanced lung cancer ( Dr Joseph Greer - Harvard Medical School, Boston, USA )

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Prof Don Dizon - Lifespan Cancer Institute, Providence, USA

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas ( Prof Don Dizon - Lifespan Cancer Institute, Providence, USA )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )

Monitoring ovarian function in oncology studies

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA

Monitoring ovarian function in oncology studies ( Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA )

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs...

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

More from ecancer